Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences has announced that the Committee for Medicinal Products for Human Use has issued a positive opinion on the company's application to extend the indication for Viread to include the treatment of chronic hepatitis B in adults.
Subscribe to our email newsletter
The application, known as a type II variation, was submitted to European regulatory authorities in October 2007. This Committee for Medicinal Products for Human Use (CHMP) positive opinion will be forwarded to the European Commission (EC), which will amend the marketing authorisation for Viread in the 27 countries of the European Union to reflect the type II variation.
The EC generally issues an updated marketing authorization within a few months following a positive CHMP recommendation.